Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

Detalles Bibliográficos
Autores principales: Fiorelli, Alfonso, Vitiello, Fabiana, Morgillo, Floriana, Santagata, Mario, Spuntarelli, Chiara, Di Domenico, Marina, Santini, Mario, Bianco, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799010/
https://www.ncbi.nlm.nih.gov/pubmed/35117144
http://dx.doi.org/10.21037/tcr.2019.06.28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799010/
https://www.ncbi.nlm.nih.gov/pubmed/35117144
http://dx.doi.org/10.21037/tcr.2019.06.28

Ejemplares similares